To compare results of low-dose tissue plasminogen activator (TPA) in children with arterial and venous thrombi relative to standard published dosing. Methods: Subjects consisted of all consecutive children with objectively confirmed thrombi for whom TPA thrombolysis was clinically ordered by the authors. Initial dosing used published standard dose (0.1-0.5 mg/kg per hour). With experience, a lowdose regimen (0.01-0.06 mg/kg per hour) was given in an attempt to derive a minimal effective dose. Results: Thirty-five children were treated with TPA. Either standard or low-dose infusions of TPA resulted in complete thrombolysis of 28 of 29 (97%) acute thrombi, while all 6 chronic thrombi had a partial response. In contrast to the recommended adult-derived dosages of 0.1 to 0.5 mg/kg per hour, the authors found that initial doses of less than 0.01 mg/kg per hour were effective in 12 of 17 patients with acute thrombosis. Neonates required 0.06 mg/kg per hour. Route of administration (local or systemic) did not affect efficacy. Major bleeding occurred in only one extremely preterm infant. Minor bleeding, primarily oozing at intravenous sites, occurred in 27% of children during TPA infusions. Prophylactic unfractionated or low-molecular-weight heparin was infused concomitant with TPA in 42% of the children and did not increase the risk of bleeding. Conclusions: TPA in very low doses appears to be safe and effective for thrombolysis of acute thromboses in most children, given appropriate patient selection.
T he optimal use, dosage, efficacy, and bleeding toxicity of tissue plasminogen activator (TPA) thrombolysis in children are unknown. Currently, anticoagulation using unfractionated heparin or low-molecular-weight heparin (LMWH) constitutes standard therapy for children with thrombosis (1) . However, pediatric hematologists are regularly asked about the use of TPA in a growing number of children who present with a wide variety of thrombi. Interest in TPA is due to the recognition that successful thrombolysis is associated with more rapid and complete restoration of blood flow and less tissue infarction (2) . Thrombolytic therapy has been shown to be more efficacious than anticoagulation alone in adults with pulmonary embolism (3) and acute coronary thrombosis (4) and for prevention of postthrombotic syndrome (PTS) secondary to iliofemoral thrombosis (5) . Children exhibit low rates of death, pulmonary embolism, thrombus propagation, thrombus recurrence, or bleeding toxicity with anticoagulant therapy; however, PTS, a clinical spectrum of swelling, pain, skin changes, and stasis ulcers that occurs as a sequela to obstructed venous flow, has been reported in 10% to 20% of children with venous thrombosis (6) (7) (8) (9) .
Several case reports and small series of pediatric patients have shown that TPA has lysed thrombi in critically ill infants and children (10) (11) (12) (13) (14) (15) (16) (17) (18) . To be clinically beneficial, novel therapies in children must show improved efficacy with little or no increase in toxicity. A recent review of the literature determined that bleeding complications requiring packed red cell transfusions occur in 20% of children receiving TPA thrombolysis (19) . Weiner et al. (10) reported intracranial hemorrhage in two of seven newborns receiving TPA. A perception of increased TPA-associated bleeding has limited the use of thrombolysis in children, and a recent report with standard doses (0.5 mg/kg per hour average dose) also revealed significant bleeding complications (20) .
Our increased appreciation that children do suffer thrombi and the rise in frequency of therapy-related thrombotic complications necessitate an investigation of the management of pediatric thromboses that includes careful investigation of TPA. Currently the dose and duration of TPA given to children are extrapolated from adult data (21) , modified by limited anecdotal experience. To design future trials evaluating TPA therapy in children, we collected clinical data through a multi-institutional North American consortium, the Pediatric Coagulation Consortium (PCC).
METHODS
The PCC, a group of pediatric hematologists interested in pediatric thrombosis, meets twice a year and communicates via e-mail. Members of the PCC elected to aggregate clinical databases regarding the use and outcome of TPA thrombolysis that was delivered using several agreed-upon clinical standards of diagnosis, eligibility criteria, monitoring, and outcome determination. Patients were treated with clinical parental consent, and an institutional review board waiver was obtained for publication of aggregated data that did not include any specific patient identifiers. Inclusion criteria included age from birth to 18 years, objective imaging diagnosis of thrombus site and extent, and adequate information regarding dose, duration, complications, and outcome. Thrombi were confirmed with ultrasound, computed tomography or angiography before and at the end of TPA infusions. No patients meeting the inclusion criteria were excluded. Thrombi that were treated within 2 weeks of symptomatic presentation were classified as acute; thrombi with a duration greater than 2 weeks were classified as chronic. Exclusion criteria for TPA thrombolysis included major surgery or central nervous system bleeding within 10 days, a major asphyxial event within 7 days (usually birth asphyxia), an invasive procedure within 72 hours, seizures within 48 hours, active bleeding, or the inability to maintain a platelet count of at least 50,000/L or fibrinogen at least 100 mg/dL with transfusion support if necessary. Thrombophilia evaluations, completed at the discretion of each investigator, included antithrombin, protein C, protein S, factor V Leiden, the prothrombin 20210 mutation, and homocysteine. Tests for antiphospholipid antibodies were routinely performed for adolescents and neonates. All coagulopathies were confirmed at least 3 months following acute thrombosis.
Administration of TPA was by local instillation into the clot through selective catheter or systemically via peripheral vein. The decision to infuse prophylactic unfractionated heparin (5-10 U/kg per hour) or LMWH (enoxaparin, 0.5 mg/kg twice daily) was made clinically by the attending hematologist based on recent reports of safety (22) .
Bleeding complications were closely monitored. Major bleeding was defined as intracranial or retroperitoneal; leading directly to death; or resulting in a drop in hemoglobin of at least 2 g/dL or requiring replacement transfusion of packed red cells, as previously published (23) . Minor bleeding was defined as oozing at the site of intravenous or other indwelling catheters or minor epistaxis, hematoma, hematuria, or melena not resulting in a drop in hematocrit.
Clots were imaged every 24 hours. It was recommended that TPA thrombolysis be discontinued when the clot was completely lysed or when the physician judged that the therapeutic attempt was unsuccessful. Complete clot lysis was defined as more than 95% resolution on imaging study at the end of the TPA infusion. Partial clot lysis was defined as 50% to 95%. PTS was evaluated using a physical examination modified from a portion of the Clinical-EtiologyAnatomic-Pathophysiologic (CEAP) clinical scale as described (24) . The CEAP score, developed by the American Venous Forum of Vascular Surgeons, grades outcome of a limb following venous thrombosis as 0 (normal), 1 (swelling), 2 (visible collaterals), 3 (induration and erythema), and 4 (ulcerations).
Children were treated with TPA based on local clinical decisions. Initially, dosing was based on published recommendations of 0.1 to 0.5 mg/kg per hour (21) . A meeting was held on Nov. 29, 1999, in Chicago, in conjunction with the Radiologic Society of North America, to discuss optimal TPA dosing in children. Three pediatric hematologists, nine interventional radiologists, and two vascular imagers attended the conference (see list of participants in the appendix). Very-low-dose TPA thrombolysis in children using 0.03 to 0.06 mg/kg per hour was developed at that meeting based on recent experience in adults (25) . Subsequently we used either standard-dose TPA or, increasingly, low-dose TPA, especially for venous thrombi.
RESULTS
In a period of 2 years, 35 children identified with thrombi at six institutions were treated with TPA. Tables 1 through  4 display patient demographics. The patients were segregated by standard versus low dose of TPA and by duration between onset of symptoms and initiation of therapy. Twenty-nine (83%) children had significant underlying medical conditions, and 23 of 35 (66%) developed thrombi in relationship to vascular trauma induced by a catheter.
Thirty-two of 35 (91%) children underwent a coagulation evaluation. Three (9%) were diagnosed with thrombophilia (factor V Leiden mutation, antithrombin deficiency, and a familial fibrinolytic defect in one each). The fibrinolytic defect, characterized by a prolonged euglobulin clot lysis time and elevated levels of plasminogen activator inhibitor type 1, was present and associated with symptomatic venous thrombosis in three generations, including the affected child. Acquired prothrombotic traits were found in five patients: a teenager had a lupus anticoagulant, a 2-year-old had a low titer of IgM anticardiolipin antibody (ACA), a newborn had very low levels of protein C and antithrombin, a 5-year-old had thrombotic thrombocytopenic purpura causing an acquired fibrinolytic defect, de- creased von Willebrand factor cleaving protein, and elevated factor VIII, and a teenager had an elevated PAI-1 associated with polycystic ovary disease. Acquired coagulopathies returned to normal only in the newborn and 2-year-old. Tables 1 through 4 display results of dose and outcome for the 35 children according to dose level and acuity of the thrombus. Complete lysis occurred in 28 of 29 (97%) acute thrombi by the end of the TPA infusion. Incomplete lysis occurred in all six patients with chronic thrombi. Only two of these six children received TPA infusions for more than 30 hours.
Five courses of low-dose therapy for acute thrombi and one course of high-dose therapy for a chronic thrombus were dose-escalated for lack of clot lysis. The five low-dose therapies resulted in complete clot lysis. Five courses of low-dose therapy for very extensive thrombi (three for acute thrombi, two for chronic thrombi) were extended beyond 48 hours, with excellent results in all.
Eight neonates treated at 1 day to 2 weeks of age all had complete clot lysis. Three term neonates were treated with conventional doses (0.1-0.5 mg/kg) for 3 to 16 hours, with complete lysis and no bleeding complications. Five neonates were treated initially with low-dose TPA (Յ0.03 mg/kg per hour in four cases, 0.06 mg/kg in one). Four required escalation to 0.06 to 0.24 mg/kg per hour for total infusion durations of 48 to 96 hours. Four of these five neonates were preterm; bleeding complications occurred in only one preterm infant.
Symptomatic PTS, consisting of pain and swelling following aerobic exercise (not with activities of daily living), along with dilated collaterals, developed in one teenager and asymptomatic dilated collaterals developed in another teenager. Both patients had underlying inflammatory diseases, extensive thrombi, and thrombophilia, and both were treated with short-duration, standard-dose TPA. TPA was discontinued at 15 hours prior to complete clot lysis in a patient with brain tumor and antithrombin deficiency secondary to recent neurosurgery.
Ten of 35 (29%) patients received TPA through local catheters; there was no difference in outcome related to the site of TPA administration.
Bleeding was observed in 9 of 35 (26%) patients; seven complications consisted of minor oozing at venipuncture sites. One child had minor hematuria and hematoma. One infusion dose was decreased (from 0.3 to 0.1 mg/kg per hour) due to minor bleeding. Bleeding complications showed no apparent relationship to TPA total dose, TPA concentration, or duration of infusion. Concomitant heparin was administered during 18 TPA infusions. Five of the 18 (28%) patients receiving heparin and TPA and 4 of 17 (21%) receiving TPA alone had bleeding (P > 0.05). In addition, bleeding did not appear to be related to patient age except in one preterm infant.
Life-threatening hemorrhage occurred in patient 29, a 28-week estimated gestational age girl with a catheterrelated right atrial thrombus and staphylococcal sepsis. Administration of TPA was begun after confirming clot progression on therapeutic heparin. The dose was progressively escalated from 0.03 to 0.24 mg/kg per hour based on progressive clot enlargement. The thrombus completely resolved, but the infant developed a subdural hematoma that required placement of a subdural drain. During the TPA infusion period, this baby received five platelet transfusions, five packed red cell transfusions, and two fresh-frozen plasma transfusions of 10 mL/kg each. Follow-up evaluation at age 7 months revealed some pressure atrophy of the right parietal lobe and normal psychomotor development for gestational age.
Patient 14 was a teenager with worsening of already very poor cardiac function (ejection fraction decreased from 15% to 9%) concomitant with chronic renal failure. He developed a huge left atrial thrombus that did not respond to therapeutic heparin. He developed an embolic stroke confirmed by computed tomography following 6 hours of TPA (0.03 mg/kg per hour) and unfractionated heparin (10 U/kg per hour).
DISCUSSION
Data regarding the outcome of thrombolysis using urokinase was previously reported from the Children's Hospital in Denver (6) . In that series of 32 children treated with combined unfractionated heparin and urokinase, clot lysis at 48 hours was associated with prevention of PTS. Human kidney cell-derived urokinase is no longer available for clinical use, thus necessitating use an alternative thrombolytic agent such as TPA.
Different dosing schedules for TPA thrombolysis have not been compared in children. A minimal effective dose cannot be determined for this group of patients, but less than or equal to 0.03 mg/kg per hour was effective for thrombolysis in 12 of 13 (92%) children initially treated for acute thrombosis. Neonates generally required 0.06 mg/kg per hour. Four neonates and one child treated initially with low doses had complete clot lysis with careful monitoring and progressive incremental increases in the dose. These low doses are comparable to the report of Knöfler et al. (16) .
Since thrombolysis does not inhibit clot propagation or directly alter hypercoagulability (26, 27) , simultaneous infusion of unfractionated heparin at 5 to 10 U/kg per hour or LMWH at half the therapeutic dose was used to prevent proximal clot extension during the TPA infusion. Bleeding complications of TPA generally involved oozing at sites of venipuncture and were minor. A subdural hematoma occurred in one preterm infant with a life-threatening intracardiac thrombus. Appropriate patient selection, including evaluation of the risks and benefits of TPA infusion as well as the predicted outcome of the underlying disease, still needs to be addressed individually.
One teenager with multiple risk factors developed symptomatic PTS. Administration of TPA was discontinued in this patient at 15 hours with some residual clot due to concerns of bleeding related to recent surgery. This patient experience supports our previous results regarding the prognostic importance of complete clot lysis before discontinuing thrombolysis in prevention of PTS. In addition, longer duration of therapy may reduce PTS in high-risk patients. Our evaluation of PTS is ongoing, but at this time it is impossible to determine from our patients the efficacy of TPA for preventing PTS in at-risk patients.
Administration of TPA should be monitored by imaging every 12 to 24 hours and stopped when clot lysis is achieved or bleeding complications occur. For safety, fibrinogen levels should be more than 100 mg/dL, and platelets more than 50,000 (21) . This limited dose study of TPA in thrombosis suggests a starting dose of 0.06 mg/kg per hour in neonates and 0.03 mg/kg per hour in non-neonates for both local and systemic thrombolysis rather than published recommendations of 0.1 to 0.5 mg/kg per hour.
In contrast to adults, children are expected to live for six or more decades, making the outcome of thrombosis a critical issue in terms of quality of life, ongoing medical morbidity, and cost. Whether thrombolysis for acute venous thrombosis will be as effective as anticoagulation in the short term (prevention of death, clot progression, and pulmonary emboli), resulting in a more rapid and complete resolution of venous obstruction and thereby reducing late recurrence and PTS, is an important clinical question. While there is no firm evidence regarding the efficacy of thrombolysis to prevent PTS, the American College of Chest Physicians recently acknowledged the positive early studies and supported clinical trials for long-term outcome (28) . This study was not controlled and thus cannot form the basis for definitive treatment recommendations. The study did demonstrate that TPA was consistently effective in lysis of acute thrombi at a dose lower than was previously thought to be therapeutic, particularly for venous thrombi.
Limitations of this study include sample size and the heterogeneity of the patient population. These will remain problematic since pediatric patients who present with thrombi are limited in number but not in the scope of underlying illnesses and ages. A prospective randomized clinical trial is necessary to verify the safety as well as the short and long-term efficacy of TPA in children.
